[go: up one dir, main page]

WO2017013271A1 - Combinaison d'un inhibiteur de la phosphatidylinositol 3-kinase delta et d'un inhibiteur de bcl-2, et utilisations et compositions pharmaceutiques associées - Google Patents

Combinaison d'un inhibiteur de la phosphatidylinositol 3-kinase delta et d'un inhibiteur de bcl-2, et utilisations et compositions pharmaceutiques associées Download PDF

Info

Publication number
WO2017013271A1
WO2017013271A1 PCT/EP2016/067699 EP2016067699W WO2017013271A1 WO 2017013271 A1 WO2017013271 A1 WO 2017013271A1 EP 2016067699 W EP2016067699 W EP 2016067699W WO 2017013271 A1 WO2017013271 A1 WO 2017013271A1
Authority
WO
WIPO (PCT)
Prior art keywords
combination
idelalisib
treatment
compound
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2016/067699
Other languages
English (en)
Inventor
Charles Dumontet
Laurence Kraus-Berthier
Ioana KLOOS
Erick MORRIS
Cody D SCHLAFF
Helena Marie-Louise FJAELLSKOG
Henry ADEWOYE
Daniel Tumas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Laboratoires Servier SAS
Gilead Sciences Inc
Original Assignee
Novartis AG
Laboratoires Servier SAS
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Laboratoires Servier SAS, Gilead Sciences Inc filed Critical Novartis AG
Publication of WO2017013271A1 publication Critical patent/WO2017013271A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the present invention relates to a combination of a Bcl-2 inhibitor and an inhibitor of phosphatidylinositol 3-kinase delta ( ⁇ 3 ⁇ ), as defined below.
  • the invention also relates to the use of said combination in the treatment of cancer, in particular a non-Hodgkin's lymphoma or leukemia, and more specifically follicular lymphoma or a mantle cell lymphoma.
  • pharmaceutical formulations suitable for the administration of such combinations are also provided.
  • the Bcl-2 inhibitor is Compound 1 : N-(4-hydroxyphenyl)-3- ⁇ 6- [((35)-3-(4-mo ⁇ holinylmethyl)-3,4-dihydro-2(lH)-isoquinolinyl)carbonyl]-l,3- benzodioxol-5-yl ⁇ -N-phenyl-5,6,7,8-tetrahydro-l-indolizine carboxamide, or a pharmaceutically acceptable salt thereof.
  • Said Compound 1, its synthesis, its use in the treatment of cancer and pharmaceutical formulations thereof, are described in WO 2013/1 10890.
  • Compound 1 is a potent and selective Bcl-2 inhibitor which is specifically disclosed in Example 1 of WO 2013/110890, the content of which is incorporated by reference.
  • Phosphatidylinositol 3-kinase delta ( ⁇ 3 ⁇ ) is critical for signal transduction downstream of B-cell receptor (BCR), cytokine/chemokine receptors, and adhesion molecules, contributing to the regulation of proliferation, differentiation, migration, and survival of B cells (Fruman et al, Cancer Discov 201 1, Vol l(7):562-572).
  • BCR B-cell receptor
  • cytokine/chemokine receptors cytokine/chemokine receptors
  • adhesion molecules contributing to the regulation of proliferation, differentiation, migration, and survival of B cells.
  • the inhibitor of phosphatidylinositol 3-kinase delta is idelalisib:
  • Idelalisib may also be referred to by the following compound name: 5-fluoro-3-phenyl-2- ⁇ (l S)-l-[(7H-purin-6-yl)amino]propyl ⁇ quinazolin-4(3H)-one (WHO Drug Information Vol 27, N°l, 2013).
  • Idelalisib also known as GS-1101 or CAL-101
  • CLL chronic lymphocytic leukemia
  • SLL small lymphocytic lymphoma
  • Idelalisib selectively inhibits PI3K5, thus blocking cell proliferation and inducing apoptosis in B cells (Lannutti et al, Blood 2011, Vol 117(2):591- 594; Fiorcari et al. PLoS One 2013 8(12):e83830). In lymphoid cell lines and primary patient samples, idelalisib blocks PI3K/AKT signaling and promotes apoptosis (Lannutti et al, Blood 2QU, Vol 117(2):591-594; Herman et al, Blood 20U, Vol 117(16):4323-4327).
  • idelalisib has demonstrated significant clinical efficacy (Kahl et al, Blood 29 May 2014; Vol 123(22):3398-3405).
  • Idelalisib is specifically disclosed in Example 107 of WO2005/113556, the content of which is incoiporated by reference, and it can be prepared using the methods described therein. Process for synthesizing idelalisib is also disclosed in WO2015/095601.
  • Apoptosis is a distinct cell death pathway that is highly regulated and initiated by various stimuli including DNA damage; however evasion of the programmed cell death is a hallmark of cancer.
  • the efficacy of many chemotherapeutic agents is dependent upon the activation of the intrinsic mitochondrial pathway which is mainly regulated by B-cell like protein-2 (Bcl-2).
  • Bcl-2 has been shown to be up-regulated in many cancers, particularly hematological malignancies such as mantle cell lymphoma (MCL) and follicular lymphoma/diffuse large B-cell lymphoma (FL/D) (Adams and Cory The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007 Vol 26: 1324-1337).
  • the present invention provides a novel combination of the Bcl-2 inhibitor Compound 1 : N-(4- hydiOxyphenyl)-3- ⁇ 6-[((35)-3-(4-moi-pholinylmethyl)-3,4-dihydro-2(lH)- isoquinolinyl)carbonyl]-l ,3-benzodioxol-5-yl ⁇ -N-phenyl-5,6,7,8-tetrahydiO-l-indolizine carboxamide, or addition salts thereof with a pharmaceutically acceptable acid or base, and the PI3K5 inhibitor idelalisib, or addition salts thereof with a pharmaceutically acceptable acid or base. It has unexpectedly been found that Compound 1 and idelalisib interact in a synergistic manner to strongly inhibit cell proliferation in certain cell line models.
  • the invention provides a combination as described herein, for use in the treatment of cancer.
  • the invention provides a combination as described herein, for use in the treatment of cancer, wherein idelalisib is first administered to the patient as a single agent treatment, and thereafter the patient is treated with the pharmaceutical combination of Compound 1 and idelalisib.
  • the invention provides the use of a combination as described herein, in the manufacture of a medicament for the treatment of cancer.
  • the invention provides a medicament containing, separately or together,
  • the invention provides a method of treating cancer, comprising administering a jointly therapeutically effective amount of:
  • Compound 1 is 7V-(4-hydroxyphenyl)-3- ⁇ 6-[((35)-3-(4- mo holinylmethyl)-3,4-dihydl ⁇ -2(lH)-isoquinolinyl)carbonyl]-l,3-benzodio ol-5-yl ⁇ -N- phenyl-5,6,7,8-tetrahydro-l-indolizine carboxamide hydrochloride.
  • FIGURES Figure 1 Summary of all calculated single agent IC 5 o values and combination index CI values calculated using Chou-Talalay method in NCEB, Granta 519, RL, DOHH2 and TMD8 cells when treated with a range of doses of Compound 1 HC1 salt and Idelalisib for 72 hours. Synergistic activity was observed across the cell line panel.
  • Figure 2. Combination index CI values calculated using Chou-Talalay method in NCEB, Granta 519, RL, DOHH2 and TMD8 cell lines when treated with a range of doses of Compound 1 HC1 salt and Idelalisib for 72 hours. Synergistic activity was observed across the cell line panel.
  • FIG. 3 2D Combination Grid Matrix Plate Set-up Abbreviations: Cmpd: Compound; DMSO: Dimethyl sulfoxide.
  • Figure 4 Summary of all calculated single agent IC 5 o values, Loewe Synergy Scores and calculated combination indices in a panel of MCL and FL/D cell lines when treated with a range of doses of Compound 1 HC1 salt and Idelalisib for 72 hours. A range of synergy from moderately synergistic to highly synergistic was observed across the cell line panel.
  • Figure 5 illustrates the inhibition and growth inhibition of the MCL line Granta-519 when treated with a range of doses of Compound 1 HC1 salt and Idelalisib for 72 hours. Moderate synergy is observed in a full concentration matrix giving a CI of 0.691 and a Loewe Synergy Score of 2.37. Percent inhibition (left matrix heat map), synergy for checkerboard combination of the two agents across a broad concentration matrix (Loewe Excess Matrix, middle heat map) and percent growth inhibition (right matrix heat map) are shown.
  • Figure 6 illustrates the inhibition and growth inhibition of the MCL line JEKO-1 when treated with a range of doses of Compound 1 HC1 salt and Idelalisib for 72 hours. Synergism is observed in a full concentration matrix giving a CI of 0.237 and a Loewe Synergy Score of 9.76. Percent inhibition (left matrix heat map), synergy for checkerboard combination of the two agents across a broad concentration matrix (Loewe Excess Matrix, middle heat map) and percent growth inhibition (right matrix heat map) are shown.
  • Figure 7 illustrates the inhibition and growth inhibition of the MCL line JVM-2 when treated with a range of doses of Compound 1 HC1 salt and Idelalisib for 72 hours.
  • Figure 8 illustrates the inhibition and growth inhibition of the FL/D line Toledo when treated with a range of doses of Compound 1 HC1 salt and Idelalisib for 72 hours. Strong synergy is observed in a full concentration matrix giving a CI of 0.0350 and a Loewe Synergy Score of 9.74. Percent inhibition (left matrix heat map), synergy for checkerboard combination of the two agents across a broad concentration matrix (Loewe Excess Matrix, middle heat map) and percent growth inhibition (right matrix heat map) are shown.
  • Figure 9 illustrates the inhibition and growth inhibition of the FL/D line SU-DHL-6 when treated with a range of doses of Compound 1 HC1 salt and Idelalisib for 72 hours.
  • the CI was unable to be calculated here due to the high degree of cell killing observed and inability to obtain a smooth IC50 curve across the dose range tested.
  • a Loewe Synergy Score of 2.05 was calculated. Percent inhibition (left matrix heat map), synergy for checkerboard combination of the two agents across a broad concentration matrix (Loewe Excess Matrix, middle heat map) and percent growth inhibition (right matrix heat map) are shown.
  • Figure 10 illustrates the inhibition and growth inhibition of the FL/D line DOH-H2 when treated with a range of doses of Compound 1 HC1 salt and Idelalisib for 72 hours. Similar to SU-DHL-6 the CI was unable to be calculated due to the high degree of sensitivity to Compound 1 and Idelalisib as a single agent. A Loewe Synergy Score of 6.33 was calculated. Percent inhibition (left matrix heat map), synergy for checkerboard combination of the two agents across a broad concentration matrix (Loewe Excess Matrix, middle heat map) and percent growth inhibition (right matrix heat map) are shown.
  • Figure 11 illustrates the single Agent IC 50 determination of Compound 1 in MCL and FL/D Panel.
  • MCL and FL/D lines plus RS4;11 were incubated for 72 hrs with Compound 1 and assessed via CTG to determine the dose at which 50 percent viability is achieved.
  • Sensitivity ranged from extremely potent ( ⁇ 100 nM) to resistant (> 5.0 ⁇ ) across the panel of cell lines.
  • Figure 12 illustrates the single Agent IC 5 o determination of Idelalisib in MCL and FL/D Panel.
  • MCL and FL/D lines were incubated for 72 hrs with Idelalisib and assessed via CTG to determine the dose at which 50 percent viability is achieved.
  • the majority of cell lines tested were either intermediately sensitive or resistant to single agent Idelalisib. DETAILED DESCRIPTION OF THE INVENTION
  • Embodiment El a combination comprising,:
  • E5. A combination according to E4, wherein the dose of idelalisib during the combination treatment is 100 mg.
  • E6. A combination according to E4, wherein the dose of idelalisib during the combination treatment is 150 mg.
  • E20 The combination for use according to any of El 5 to El 8, wherein the cancer is B-cell lymphoma.
  • E22 The combination for use according to E21, wherein the cancer is indolent non- Hodgkin's lymphoma.
  • E23 The combination for use according to any of El 5 to El 8, wherein the cancer is follicular lymphoma.
  • E24. The combination for use according to any of El 5 to El 8, wherein the cancer is follicular lymphoma/diffuse large B-cell lymphoma (FL/D).
  • E26 The combination for use according to any of El 5 to El 8, wherein the cancer is chronic lymphocytic leukemia.
  • E28 The combination for use according to E27, wherein when idelalisib is first administered to the patient as a single agent treatment, the dose of idelalisib is 150 mg.
  • E29 The combination for use according to E27 or E28, wherein when idelalisib is first administered to the patient as a single agent treatment, idelalisib is administered twice a day.
  • E30 The combination for use according to E27, E28 or E29, wherein when idelalisib is first administered to the patient as a single agent treatment, it is administered in one treatment cycle.
  • E33 The use according to E32, wherein the cancer is a non-Hodgkin's lymphoma, follicular lymphoma or mantle cell lymphoma.
  • E34 The use according to E32, wherein the cancer is chronic lymphocytic leukemia.
  • E35 A medicament containing, separately or together,
  • a method of treating cancer comprising administering a jointly therapeutically effective amount of (a) Compound 1 : N-(4-hydroxyphenyl)-3- ⁇ 6-[((35)-3-(4- moi holinylmethyl)-3,4-dihydiO-2(lH)-isoquinolinyl)carbonyl]-l,3-benzodioxol-5-yl ⁇ -N- phenyl-5,6,7,8-tetrahydro-l -indolizine carboxamide, or addition salts thereof with a pharmaceutically acceptable acid or base, and
  • Combination refers to either a fixed dose combination in one unit dosage form (e.g., capsule, tablet, or sachet), non-fixed dose combination, or a kit of parts for the combined administration where a compound of the present invention and one or more combination partners (e.g. another drug as explained below, also referred to as “therapeutic agent” or “co-agent”) may be administered independently at the same time or separately within time intervals, especially where these time intervals allow that the combination partners show a cooperative, e.g. synergistic effect.
  • a combination partners e.g. another drug as explained below, also referred to as "therapeutic agent” or "co-agent”
  • co-administration or “combined administration” or the like as utilized herein are meant to encompass administration of the selected combination partner to a single subject in need thereof (e.g. a patient), and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
  • fixed dose combination means that the active ingredients, e.g. a compound of formula (I) and one or more combination partners, are both administered to a patient simultaneously in the form of a single entity or dosage.
  • non-fixed dose combination means that the active ingredients, e.g. a compound of the present invention and one or more combination partners, are both administered to a patient as separate entities either simultaneously or sequentially, with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient.
  • cocktail therapy e.g. the administration of three or more active ingredients.
  • Cancer means a class of disease in which a group of cells display uncontrolled growth. Cancer types include haematological cancer (lymphoma and leukemia) and solid tumors including carcinoma, sarcoma, or blastoma. In particular “cancer” refers to a non- Hodgkin's lymphoma, and more specifically follicular lymphoma, or a mantle cell lymphoma. Chronic lymphocytic leukemia is also particularly preferred.
  • joint therapeutically effective means that the therapeutic agents may be given separately (in a chronologically staggered manner, especially a sequence-specific manner) in such time intervals that they prefer, in the warm-blooded animal, especially human, to be treated, still show a (preferably synergistic) interaction (joint therapeutic effect). Whether this is the case can, inter alia, be determined by following the blood levels, showing that both compounds are present in the blood of the human to be treated at least during certain time intervals.
  • “Synergistically effective” or “synergy” means that the therapeutic effect observed following administration of two or more agents is greater than the sum of the therapeutic effects observed following the administration of each single agent.
  • Follicular lymphoma/diffuse large B-cell lymphoma refers to follicular lymphoma with progression to diffuse large B-cell lymphoma. This corresponds to the evolution of a clinically indolent non-Hodgkin lymphoma to a high-grade, aggressive non- Hodgkin lymphoma (Roulland et al, Adv. Immunol. 2011 111 :1-46. doi: 10.1016/B978-0- 12-385991-4.00001-5; Davies et al, Br J Haematol. 2007 January; 136(2):286-293. doi:10.111 l/j.l365-2141.2006.06439.x).
  • Treatment cycle means a period of time to receive treatment according to a determined administration schedule after which the efficacy of the treatment is assessed by evaluating the tumour response. The acceptability profile is also evaluated. Preferably, treatment cycle corresponds to 28 day cycle.
  • Follicular lymphoma includes both relapsed and refractory follicular lymphoma.
  • Mantle cell lymphoma includes both relapsed and refractory mantle cell lymphoma.
  • the term “treat”, “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
  • “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • “treat”, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
  • a subject is "in need of a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
  • a method for treating a patient who exhibits one or more symptoms associated with a B-cell malignancy is provided herein.
  • the patient is at an early stage of a B-cell malignancy. In other embodiments, the patient is at an advanced stage of a B-cell malignancy.
  • provided herein is a method for treating a patient who is undergoing one or more standard therapies for treating a B-cell malignancy, such as chemotherapy, radiotherapy, immunotherapy, and/or surgery.
  • a Compound 1 and idelalisib, as described herein may be administered before, during, or after administration of chemotherapy, radiotherapy, immunotherapy, and/or surgery.
  • a patient "refractory" to an anti-B-cell malignancy therapy means they do not respond to the particular treatment, also referred to as resistant.
  • the B-cell malignancy may be resistant to treatment from the beginning of treatment, or may become resistant during the course of treatment, for example after the treatment has shown some effect on the B-cell malignancy, but not enough to be considered a remission or partial remission.
  • a patient in "relapse" means that the B-cell malignancy has returned or the signs and symptoms of the B-cell malignancy have returned after a period of improvement, e.g. after a treatment has shown effective reduction in the B-cell malignancy, such as after a subject is in remission or partial remission.
  • the patient is (i) refractory to at least one anti-B-cell malignancy therapy, or (ii) in relapse after treatment with at least one anti-B-cell malignancy therapy, or both (i) and (ii).
  • the patient is refractory to at least two, at least three, or at least four anti-B-cell malignancy therapies (including, for example, standard or experimental chemotherapies).
  • a patient who is sensitized is a patient who is responsive to the treatment involving administration of Compound 1 in combination with idelalisib, as described herein, or who has not developed resistance to such treatment.
  • Having an administration schedule that reduces the incidence of tumour lysis syndrome in a cancer patient or patient group means an administration schedule wherein the Bcl-2 inhibitor is administered according to a dose ramp-up schedule.
  • Dose ramp-up schedule means an administration schedule wherein the drug starts being administered at lower dose, which dose is then gradually increased up to the maximum tolerated dose (MTD)/ recommended dose.
  • MTD maximum tolerated dose
  • “Medicament” means a pharmaceutical composition, or a combination of several pharmaceutical compositions, which contains one or more active ingredients in the presence of one or more excipients.
  • 'DLBCL' means diffuse large B-cell lymphoma.
  • 'ALL' means acute lymphoblastic leukemia.
  • 'CLL' means chronic lymphocytic leukemia.
  • isotopically labeled forms of compounds detailed herein.
  • Isotopically labeled compounds have structures depicted by the fomiulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to 2 H (deuterium, D), 3 H (tritium), n C, 13 C, 14 C, 15 N, 1 8 F, 31 P, 32 P, 35 S, 36 C1 and 125 I.
  • isotopically labeled compounds of the present disclosure for example those into which radioactive isotopes such as 3 H, 13 C and I4 C are incorporated, are provided.
  • Such isotopically labeled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of subjects ⁇ e.g. humans).
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • any pharmaceutically acceptable salts, or hydrates as the case may be.
  • the compounds disclosed herein may be varied such that from 1 to n hydrogens attached to a carbon atom is/are replaced by deuterium, in which n is the number of hydrogens in the molecule.
  • Such compounds may exhibit increased resistance to metabolism and are thus useful for increasing the half life of the compound when administered to a mammal. See, for example, Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci. 5(12):524-527 (1984).
  • Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.
  • Deuterium labeled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to absorption, distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements and/or an improvement in therapeutic index.
  • An 18 F labeled compound may be useful for PET or SPECT studies.
  • Isotopically labeled compounds of this disclosure can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • deuterium in this context is regarded as a substituent in the compounds provided herein.
  • concentration of such a heavier isotope, specifically deuterium may be defined by an isotopic enrichment factor.
  • any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom.
  • a position is designated specifically as “H” or “hydrogen”
  • the position is understood to have hydrogen at its natural abundance isotopic composition.
  • any atom specifically designated as a deuterium (D) is meant to represent deuterium.
  • the proportion of active ingredients by weight is from 5 to 50 %.
  • compositions according to the invention there will be more especially used those which are suitable for administration by the oral, parenteral and especially intravenous, per- or trans-cutaneous, nasal, rectal, perlingual, ocular or respiratory route, more specifically tablets, dragees, sublingual tablets, hard gelatin capsules, glossettes, capsules, lozenges, injectable preparations, aerosols, eye or nose drops, suppositories, creams, ointments, dermal gels etc.
  • compositions according to the invention comprise one or more excipients or carriers selected from diluents, lubricants, binders, disintegration agents, stabilisers, preservatives, absorbents, colourants, sweeteners, flavourings etc.
  • excipients or carriers selected from diluents, lubricants, binders, disintegration agents, stabilisers, preservatives, absorbents, colourants, sweeteners, flavourings etc.
  • ⁇ as diluents: lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycerol,
  • ⁇ as lubricants silica, talc, stearic acid and its magnesium and calcium salts, polyethylene glycol,
  • binders magnesium aluminium silicate, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidone,
  • ⁇ as disintegrants agar, alginic acid and its sodium salt, effervescent mixtures.
  • the compounds of the combination may be administered simultaneously or sequentially.
  • the administration route is preferably the oral route, and the corresponding pharmaceutical compositions may allow the instantaneous or delayed release of the active ingredients.
  • the compounds of the combination may moreover be administered in the form of two separate pharmaceutical compositions, each containing one of the active ingredients, or in the form of a single pharmaceutical composition, in which the active ingredients are in admixture.
  • composition of Compound 1 HCl salt film-coated tablet containing 50 mg and 100 mg of drug substance
  • Hematological Non-Hodgkin Lymphoma cell lines (Mantle cell lymphoma: NCEB, GRANTA; Follicular lymphoma : RL, DOHH2 and Diffuse Large B cell Lymphoma: TMD8) were obtained from ATCC or DSMZ.
  • NCEB, Granta 519, RL, DOHH2 and TMD8 cells were exposed in triplicate to a serial dilution of each agent or both in combination using the constant ratio combination design for 72 hours, followed by the MTT assay for cell viability determination.
  • EXAMPLE 2 Combination activity of N-(4-hydroxyphenyl)-3-i6-r((3S)-3-(4- morphoIinylmethvn-3,4-dihydro-2(lH)-isoquinolinvi)carbonyl1-l,3-benzodioxoI-5- yl ⁇ -N-phenyl-5,6,7,8-tetrahydro-l-indoIizine carboxamide (Compound 1) hydrochloride salt in combination with idelalisib (Compound 2) in MCL and FL/D cell lines in vitro
  • RPMI Roswell Park Memorial Institute 1640
  • HI FBS Gibco Invitrogen Life Science Technologies
  • JEKO-1 and DOH-H2 cells were grown in RPMI 1640 supplemented with 20% HI FBS and maintained at 37°C, 5% C0 2 .
  • Suspension cultures were seeded at a density of 10,000 cells per well in a tissue culture treated black walled 96-well flat bottom plate (Corning; Catalog Number: 3904) and allowed to equilibrate overnight at 37°C, 5% C0 2 .
  • the following day cells were dosed with Compound 1 HCl salt and Idelalisib at a final dose range of 10 ⁇ to 0.013717 ⁇ using a 3 -fold dilution series.
  • Suspension cultures were seeded at a density of 10,000 cells per well in a tissue culture treated black walled 96-well flat bottom plate (Coming; Catalog Number: 3904) and allowed to equilibrate overnight at 37°C, 5% C0 2 .
  • the following day cells were dosed with Compound 1 HC1 salt and Idelalisib according to Figure 3 using a final dose range from 10 ⁇ to 0.013717 ⁇ using a 3-fold dilution series either as single agents or combined.
  • plates were then analyzed for ATP levels using the Cell Titer Glo Assay (CTG; Promega; Catalog Number: G7572) according to the manufacturer's instructions and read on the Envision Plate Reader.
  • CCG Cell Titer Glo Assay
  • Combination activity was detemiined according to the Loewe additivity model (Greco WR et al, Pharmacol Rev. 1995 Jun, Vol 47(2):331-85 PubMed PMID: 7568331) using a custom-built software (Combination Analysis Module). Briefly, for each combination of two compounds, the combination effect is calculated as the difference between the measured inhibition and the inhibition according to the Loewe additivity model.
  • Combination index (CI) is derived by the following equation (Chou TC, Pharmacol Rev. 2006 Sep, Vol 58(3):621-81 Erratum in: Pharmacol Rev. 2007 Mar, Vol 59(1):124. PubMed PMID: 16968952) and is freely available through the Combosyn software (www. combo syn. com) :
  • EC 50 (A) and EC 5 o(B) are the concentration of drug A and B that individually cause 50% inhibition
  • the study has two parts (a dose escalation part and a 2-arm dose expansion part). Approximately 65 patients will be enrolled in the study, with approximately 25 patients in the dose escalation, and approximately 20 patients each of FL and MCL in dose expansion.
  • the dose escalation part of the study is designed to characterize the safety and tolerability of Compound 1 hydrochloride salt in combination with idelalisib.
  • the dose expansion part will further evaluate the safety, tolerability and preliminary antitumor activity in separate treatment arms for FL and MCL. All patients will receive a run-in with single-agent idelalisib at 150 mg twice a day for 28 days. Thereafter, patients at low/intermediate risk for tumor lysis syndrome will receive combination treatment at the MTD/RDE. Patients with MCL at high risk for tumor lysis syndrome will be dosed more cautiously with incremental doses of Compound 1 hydrochloride salt up to MTD/RDE combined with idelalisib at a fixed dose (RDE).
  • MTD maximum tolerated dose
  • RDE recommended dose expansion
  • the treatment period will start on Cycle 1 Day 1 with combination treatment (idelalisib and Compound 1 hydrochloride salt) administered in 28 day cycles.
  • the treatment period will start on Cycle 1 Day 1 with idelalisib 150 mg twice a day for 28 days followed by combination treatment (idelalisib and Compound 1 hydrochloride salt) administered in 28 day cycles.
  • Patients should continue treatment until completion of 4 cycles of study drug(s) after achieving complete release, disease progression, occurrence of unacceptable toxicity that precludes any further treatment, patient's death, and/or treatment is discontinued at the discretion of the investigator or by patient request.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une combinaison contenant un composant N-(4-hydroxyphényl)-3-{6-[((3S)-3-(4-morpholinylméthyl)- 3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1, 3-benzodioxol-5-yl}-N-phényl-5, 6,7,8-tetrahydro-l-indolizine carboxamide ou un sel pharmaceutiquement acceptable de ce dernier, et un composant idelalisib ou un sel pharmaceutiquement acceptable de ce dernier, ainsi que des compositions et des utilisations de ladite combinaison.
PCT/EP2016/067699 2015-07-23 2016-07-25 Combinaison d'un inhibiteur de la phosphatidylinositol 3-kinase delta et d'un inhibiteur de bcl-2, et utilisations et compositions pharmaceutiques associées Ceased WO2017013271A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562195971P 2015-07-23 2015-07-23
US62/195,971 2015-07-23
EP15306323 2015-08-27
EP15306323.5 2015-08-27

Publications (1)

Publication Number Publication Date
WO2017013271A1 true WO2017013271A1 (fr) 2017-01-26

Family

ID=54014754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/067699 Ceased WO2017013271A1 (fr) 2015-07-23 2016-07-25 Combinaison d'un inhibiteur de la phosphatidylinositol 3-kinase delta et d'un inhibiteur de bcl-2, et utilisations et compositions pharmaceutiques associées

Country Status (1)

Country Link
WO (1) WO2017013271A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110890A1 (fr) * 2012-01-24 2013-08-01 Les Laboratoires Servier Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110890A1 (fr) * 2012-01-24 2013-08-01 Les Laboratoires Servier Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAO Y ET AL: "The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells", BRITISH JOURNAL OF HAEMATOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 170, no. 1, 12 January 2015 (2015-01-12), pages 134 - 138, XP002745558, ISSN: 0007-1048, [retrieved on 20150112], DOI: 10.1111/BJH.13278 *
CHOUDHARY G S ET AL: "MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies", CELL DEATH & DISEASE, NATURE PUBLISHING GROUP, GB, vol. 6, 15 January 2015 (2015-01-15), pages e1593 - 1, XP002745557, ISSN: 2041-4889, [retrieved on 20150115], DOI: 10.1038/CDDIS.2014.525 *
DATABASE BIOSIS, [online] 19 November 2010 (2010-11-19), JIN LINHUA ET AL: "Efficacy and Mechanisms of Apoptosis Induction by Simultaneous Inhibition of PI3K with GDC-0941 and Blockade of Bcl-2 (ABT-737) or FLT3 (Sorafenib) In AML Cells In the Hypoxic Bone Marrow Microenvironment", XP002678287, retrieved from BIOSIS Database accession no. PREV201100423323 *
KUTSCH N ET AL: "Emerging therapies for refractory chronic lymphocytic leukemia", LEUKEMIA AND LYMPHOMA 20150201 INFORMA HEALTHCARE GBR, vol. 56, no. 2, February 2015 (2015-02-01), pages 285 - 292, XP009188195, ISSN: 1042-8194 *
ZHU S ET AL: "PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, UNIVERSITY PRESS CAROL DAVILA, BUCHAREST, RO, vol. 17, no. 3, March 2013 (2013-03-01), pages 377 - 385, XP002740727, ISSN: 1582-1838, [retrieved on 20130207], DOI: 10.1111/JCMM.12019 *

Similar Documents

Publication Publication Date Title
JP7520189B2 (ja) 組み合わせ療法
Zhao et al. The clinical development of MEK inhibitors
EP3515446B1 (fr) Combinaisons thérapeutiques comprenant un inhibiteur de raf et un inhibiteur d'erk
CN103764144B (zh) Pi3k抑制剂与mek抑制剂的协同组合
JP7278331B2 (ja) がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法
JP2021525768A (ja) Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法
CA2914310A1 (fr) Combinaisons pharmaceutiques
AU2021267213B2 (en) Pharmaceutical combination comprising TNO155 and nazartinib
WO2020211860A1 (fr) Composé de quinoléine ou sel pharmaceutiquement acceptable de celui-ci pour le traitement du sarcome d'ewing
JP2017533963A (ja) 結腸直腸癌の処置に使用するためのアピリモド
TW202529768A (zh) 癌症治療的療法
TW202118488A (zh) Mdm2抑制劑的藥物組合物及其在預防和/或治療疾病中的用途
WO2018158225A1 (fr) Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-2, utilisations et compositions pharmaceutiques associées
RU2674995C2 (ru) Фармацевтические комбинации
CN112533600B (zh) 用于治疗小细胞肺癌的喹啉衍生物
JP2023509191A (ja) 癌を治療するための組み合わせ療法
WO2017013271A1 (fr) Combinaison d'un inhibiteur de la phosphatidylinositol 3-kinase delta et d'un inhibiteur de bcl-2, et utilisations et compositions pharmaceutiques associées
JP2024517788A (ja) Ｍｐｎｓｔの処置のための化合物及び組成物
IL300145A (en) A combination of a BCL-2 inhibitor and a hypomethylating agent for the treatment of cancer, its uses and pharmaceutical preparations
HK1215789B (en) Pharmaceutical combinations
HK40004186A (en) Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
HK40004186B (en) Therapeutic combinations comprising a raf inhibitor and a erk inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16745444

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16745444

Country of ref document: EP

Kind code of ref document: A1